Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
Biochemical and Biophysical Research Communications|August 6, 2009
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancerMelissa Crawford, Kara Batte, Lianbo Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 7, 2016
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 AntibodiesTakehito Shukuya, Keita Mori, Joseph M Amann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2009
MicroRNAs in the pathogenesis of Lung CancerXin Wu, Melissa G Piper-Hunter, Melissa Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|June 8, 2020
Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung CancerMichael F Sharpnack, Ju Hwan Cho, Travis S Johnson, et al.
Clinical Epigenetics|April 21, 2021
Advances in epigenetic therapeutics with focus on solid tumorsNing Jin, Tiffany L George, Gregory A Otterson, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)Erin M Bertino, Tanios Bekaii-Saab, Soledad Fernandez, et al.
Molecular Cancer Therapeutics|July 27, 2016
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck CancerErin M Bertino, Elizabeth L McMichael, Xiaokui Mo, et al.
Lancet (London, England)|May 31, 2011
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialRoy S Herbst, Rafat Ansari, Frederique Bustin, et al.
International Journal of Cancer|March 16, 2019
Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic miceWenrui Duan, Li Gao, Arjun Kalvala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancerTamila Kindwall-Keller, Gregory A Otterson, Donn Young, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
Biochemical and Biophysical Research Communications|August 6, 2009
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancerMelissa Crawford, Kara Batte, Lianbo Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 7, 2016
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 AntibodiesTakehito Shukuya, Keita Mori, Joseph M Amann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2009
MicroRNAs in the pathogenesis of Lung CancerXin Wu, Melissa G Piper-Hunter, Melissa Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|June 8, 2020
Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung CancerMichael F Sharpnack, Ju Hwan Cho, Travis S Johnson, et al.
Clinical Epigenetics|April 21, 2021
Advances in epigenetic therapeutics with focus on solid tumorsNing Jin, Tiffany L George, Gregory A Otterson, et al.
Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)Erin M Bertino, Tanios Bekaii-Saab, Soledad Fernandez, et al.
Molecular Cancer Therapeutics|July 27, 2016
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck CancerErin M Bertino, Elizabeth L McMichael, Xiaokui Mo, et al.
Lancet (London, England)|May 31, 2011
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialRoy S Herbst, Rafat Ansari, Frederique Bustin, et al.
International Journal of Cancer|March 16, 2019
Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic miceWenrui Duan, Li Gao, Arjun Kalvala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancerTamila Kindwall-Keller, Gregory A Otterson, Donn Young, et al.
Pageof 16